John Bluth

John Bluth has served as the Senior Vice President of Investor Relations and Corporate Communications at BioCryst Pharmaceuticals since December of 2017. Prior to joining BioCryst, John served as the Executive Vice President of Investor Relations and Corporate Communications at Cempra Pharmaceuticals from August of 2016 to December of 2017. At Cempra, John led the company through a successful reverse merger process with Melinta Therapeutics in November of 2017.

Before their time at Cempra, John served as the Senior Vice President of Investor Relations and Group Communications at Elster from October of 2009 to August of 2012. In this role, John was responsible for leading Elster's global investor relations program and communicating the company's strategy to financial analysts and investors.

John began their career in investor relations and corporate communications at CV Therapeutics in April of 2002, where they served as the Vice President of Investor Relations and Corporate Communications until June of 2009. During their time at CV Therapeutics, John successfully established the company's investor relations program and communicated CV Therapeutics' strategy to financial analysts and investors.

John Bluth has a Bachelor's degree in Biology from Cornell University.

Some of their coworkers include Alane Barnes - SVP & Chief Legal Officer, Megan Sniecinski - Senior Vice President, Chief Business Officer, and Carol Ohmstede - Vice President, Project Management. John Bluth reports to Jon P. Stonehouse, President & CEO.